News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Colby Pharmaceutical Announces SBIR Award for JunD Oncoprotein-Androgen Receptor (AR) Interaction Inhibitor Drugs in Novel Prostate Cancer Therapy


10/1/2012 10:08:12 AM

SAN JOSE, Calif.--(BUSINESS WIRE)--Colby Pharmaceutical Company (Colby), a private San Jose, CA biopharmaceutical company, announced that it received a National Cancer Institute (NCI) SBIR funding award for small molecule inhibitors of interactions between Androgen Receptor (AR) Protein with JunD Oncoprotein for treatment of prostate cancer (PCa).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES